B
BioNexus Gene Lab Corp
Period
FY 2025
Revenue
$7.42M
Net Income
$-2.98M
Total Assets
$9.25M
Equity
$8.61M
Shares Out
2.42M
Op. Cash Flow
$-1.84M
Business
BioNexus Gene Lab Corp operates two principal business divisions through wholly-owned Malaysian subsidiaries: Chemrex, which distributes chemical raw materials (primarily fibre-reinforced polymers) to industrial manufacturers in Southeast Asia, and MRNA Scientific, which provides blood-based genomic screening services for early disease risk assessment. In November 2025, the company obtained an exclusive Southeast Asia license to the VitaGuard™ minimal residual disease platform for oncology screening. The company serves manufacturers, healthcare providers, and hospitals across Malaysia and broader Southeast Asia.
Summary from 10-K filed 2026-04-14
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| REVENUE (including $68,104 and $112,556 of revenue from related party for the year ended December 31, 2025 and 2024 respectively) | 7 | 10 | 10 | 11 | 13 | |
| COST OF REVENUE (including $9,503 and $297,736 of cost of revenue from related party for the year ended December 31, 2025 and 2024, respectively) | −6 | −8 | −8 | −10 | −11 | |
| GROSS PROFIT | 1 | 1 | 1 | 1 | 2 | |
| Dividend income | 22,112 | 68,130 | 61,409 | — | — | |
| Interest income | 83,888 | 147,641 | 68,675 | — | — | |
| Fair value gain on investments in equity securities | 0 | 69,476 | 306,614 | — | — | |
| Gain on disposal of investments in equity securities | 27,201 | 38,409 | — | — | — | |
| Reversal of expected credit losses | 144,767 | 2 | 0 | — | — | |
| Gain from foreign exchange | 94,664 | 0 | — | — | — | |
| Others | 59,485 | 59,405 | 42,093 | 179,283 | 66,491 | |
| TOTAL OTHER INCOME | 432,117 | 2 | 486,036 | — | — | |
| Sales and marketing | −2 | −2 | −596,858 | — | — | |
| Research and development | −50,670 | −47,511 | −54,982 | — | — | |
| General and administrative (including $4,206 and $1,969 of rental expenses to related party for the year ended December 31, 2025 and 2024, respectively) | −2 | −2 | −2 | −2 | −1 | |
| Share-based compensation | −794,770 | −141,000 | — | — | — | |
| Fair value loss on investments in equity securities | −93,965 | 0 | — | — | — | |
| Provision for expected credit losses | −271,211 | −883,533 | — | — | — | |
| TOTAL OPERATING EXPENSES | −4 | −5 | −4 | — | — | |
| LOSS FROM OPERATIONS | −3 | −2 | −3 | −291,177 | 1 | |
| FINANCE COSTS | −19,542 | −21,146 | −13,929 | — | — | |
| LOSS BEFORE TAXES | −3 | −2 | −3 | −303,656 | 1 | |
| Deferred tax | 0 | −12,305 | 17,359 | — | −26,736 | |
| Income tax | 0 | 15,799 | — | — | — | |
| Tax expense | 0 | 3,494 | −21,526 | −52,310 | −291,283 | |
| NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS | −3 | −2 | −3 | −355,966 | 751,571 | |
| Foreign currency translation gain | 434,251 | 122,294 | — | — | — | |
| COMPREHENSIVE LOSS | −3 | −1 | −3 | −664,766 | 517,625 | |
| Earnings per share - Basic and diluted | −1.61 | −0.9 | — | — | — | |
| Weighted average number of common stocks outstanding, Basic and Diluted # | 2 | 2 | — | — | — |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2023 2023-09-30 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash and bank balances | 2 | 2 | — | — | — | |
| Fixed deposits placed with financial institutions (including $1,553,322 and $1,490,461 of fixed deposits with original maturities more than 3 months as of December 31, 2025 and December 31, 2024 respectively) | 2 | 3 | — | — | — | |
| Trade receivables, net of allowance for credit losses of $703,995 and $517,877 as of December 31, 2025 and December 31, 2024 respectively (including $31,420 and $47,272 of trade receivables from related party as of December 31, 2025 and December 31, 2024 respectively) | 505,885 | 1 | — | — | — | |
| Other receivables, deposits and prepayments | 81,728 | 203,660 | — | — | — | |
| Other assets | 83,333 | 0 | — | — | — | |
| Tax recoverable | 61,384 | 84,167 | 57,588 | — | 31,551 | |
| Inventories (including goods in transit of $Nil and $188,797 as of December 31, 2025 and December 31, 2024 respectively) | 676,703 | 1 | 1 | — | 977,807 | |
| Total current assets | 5 | 7 | 8 | — | 6 | |
| Operating lease right-of-use assets | 177,737 | 215,243 | 141,544 | 141,544 | 55,730 | |
| Property, plant and equipment, net | 2 | 2 | 2 | — | 2 | |
| Investments in equity securities | 2 | 1 | — | — | — | |
| Total non-current assets | 4 | 3 | 3 | — | 3 | |
| TOTAL ASSETS | 9 | 10 | 11 | — | 9 | |
| Trade payables | 2,335 | 2 | — | — | — | |
| Other payables and accrued liabilities | 401,611 | 284,108 | 180,912 | — | 103,370 | |
| Current portion of operating lease liabilities | 59,147 | 50,816 | 34,632 | — | 16,569 | |
| Advance payment from customer | 8,385 | 95,879 | 0 | — | 23,123 | |
| Amount owing to directors | 49,479 | 17,174 | — | — | — | |
| Total current liabilities | 520,957 | 2 | 2 | — | 2 | |
| Non-current portion of operating lease liabilities | 116,899 | 159,741 | 98,763 | — | 40,206 | |
| Total non-current liability | 116,899 | 159,741 | 111,018 | — | 71,072 | |
| TOTAL LIABILITIES | 637,856 | 2 | 2 | — | 2 | |
| As at December 31, 2025, common stock, no par value; 300,000,000 shares authorized and 2,417,314 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding. As at December 31, 2024, common stock, no par value; 300,000,000 shares authorized and 1,796,766 shares outstanding, and preferred stock, no par value; 30,000,000 share authorized and no shares outstanding (on a post-reverse stock split basis)*. | 20 | 17 | 17 | — | 11 | |
| Additional paid in capital | −5 | −5 | −5 | — | −5 | |
| Accumulated deficit | −6 | −3 | −2 | — | 1 | |
| Accumulated other comprehensive losses | −120,749 | −555,000 | −677,294 | — | −409,062 | |
| TOTAL STOCKHOLDERS' EQUITY | 9 | 8 | 10 | — | 7 | |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | 9 | 10 | 11 | — | 9 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −3 | −2 | — | — | — | |
| Amortization of right-of-use asset | 56,434 | 48,983 | — | — | — | |
| Allowances for expected credit losses | 271,211 | 883,533 | 6,261 | 4,165 | 3,809 | |
| Recoveries for expected credit losses | −144,767 | −2 | — | — | — | |
| Bad debts written off | 0 | 6,344 | — | — | — | |
| Depreciation of property, plant and equipment | 111,873 | 104,160 | 83,253 | 91,427 | 91,282 | |
| Dividend income | −22,112 | −68,130 | — | — | — | |
| Fair value loss/(gain) on investments in equity securities, net | 93,965 | −69,476 | — | — | — | |
| Loss arising from settlement of supplier contract dispute | 0 | 29,534 | 0 | — | — | |
| Gain on disposal of investments in equity securities | −27,201 | −38,409 | — | — | — | |
| Loss on lease termination | 0 | 1,384 | 0 | — | — | |
| Impairment on property | 0 | 40,173 | — | — | — | |
| Operating loss before working capital changes | −2 | −2 | — | — | — | |
| Inventories | 711,921 | −250,854 | −160,387 | 544,108 | −345,745 | |
| Trade, other receivables and other assets | 782,841 | 147,760 | — | — | — | |
| Trade and other payables | −1 | 204,342 | −381,293 | −119,695 | −1 | |
| Advance payment from customer | −87,494 | 95,879 | −23,123 | −7,184 | 30,307 | |
| Operating lease liabilities | −34,511 | −42,895 | 76,620 | −126,686 | −20,169 | |
| Tax recoverable/(liabilities) | 22,783 | −38,834 | −44,648 | — | — | |
| Net cash used in operating activities | −2 | −2 | −2 | 551,822 | 9,161 | |
| Acquisition of investments in equity securities | −9,159 | −492,732 | — | — | — | |
| Dividend income | 22,112 | 68,130 | — | — | — | |
| Change in fixed deposits placed with original maturities more than three months | −62,860 | −78,835 | — | — | — | |
| Purchase of plant and equipment | −36,971 | −226,989 | −149,398 | 0 | −3,162 | |
| Proceeds from disposal of investments in equity securities | 1 | 1 | — | — | — | |
| Proceeds from settlement of supplier contract dispute | 0 | 79,851 | — | — | — | |
| Net cash generated from investing activities | 944,751 | 418,202 | −2 | −450,498 | −490,574 | |
| Advances from Directors | 32,305 | 3,975 | — | — | — | |
| Cash paid for fractional shares in reverse stock split | −775 | 0 | — | — | — | |
| Share subscription | 267,311 | 0 | — | — | — | |
| Net cash generated from financing activities | 298,841 | 3,975 | 6 | 108,168 | −28,222 | |
| Foreign currency translation adjustment | 194,207 | 40,339 | −259,679 | −214,547 | −154,138 | |
| NET CHANGE IN CASH AND CASH EQUIVALENTS | −400,583 | −2 | 2 | −5,055 | −663,773 | |
| Fixed deposits placed with financial institutions with original maturities of three months or less | 103,014 | 1 | 2 | 2 | 2 | |
| Cash and bank balances | 2 | 2 | — | — | — | |
| Cash and cash equivalents, end of financial year | 2 | 3 | 5 | — | — | |
| Interest paid | −6,865 | −9,351 | −8,877 | −12,479 | −12,973 | |
| Income tax refunded | 43,655 | 0 | 312 | — | 0 | |
| Income tax paid | −14,823 | −40,380 | −66,973 | −170,447 | −226,770 | |
| Acquisition of investment via share exchange | −2 | 0 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is BioNexus Gene Lab Corp's CIK number?
BioNexus Gene Lab Corp's SEC CIK number is 0001737523 (1737523). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find BioNexus Gene Lab Corp's SEC filings?
All of BioNexus Gene Lab Corp's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.